Table 5.
Changes in aortic pulse wave velocity over 24 weeks in the SCaRF trial
| Treatment group | Baseline |
Week 12 |
Week 24 |
Within-group treatment effect estimate (95% CI) | P Value | Treatment effect estimate vs. CC (95% CI) | P value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | |||||
| PWV, m/s | ||||||||||
| CC | 8 | 8.9 (1.7) | 8 | 9.4 (1.7) | 8 | 10.2 (1.9) | 1.1 (0.2 to 2.0) | 0.01 | — | — |
| SH+SC | 15 | 9.2 (1.0) | 12 | 8.6 (1.0) | 13 | 7.9 (0.8) | –0.9 (–1.4 to –0.5) | 0.01 | –2.0 (–2.9 to –1.1) | 0.01 |
| SH | 9 | 9.5 (0.9) | 6 | 8.7 (0.6) | 7 | 8.2 (0.9) | –1.0 (–1.7 to –0.3) | 0.01 | –2.0 (–3.0 to –0.9) | 0.01 |
| SC | 6 | 8.9 (1.1) | 6 | 8.5 (1.3) | 6 | 7.7 (0.8) | –1.0 (–1.7 to –0.3) | 0.01 | –2.1 (–3.2 to –1.0) | 0.01 |
CC, calcium carbonate; SC, sevelamer carbonate; SCaRF, Sevelamer Versus Calcium to Reduce Fetuin-A-containing Calciprotein Particles in Dialysis; SH, sevelamer hydrochloride; PWV, pulse wave velocity; 95% CI, 95% confidence interval;
PWV values are expressed as mean (SD) using all available data (N). Mixed-effects analyses are adjusted for mean arterial pressure, heart rate, and baseline PWV.